ThromboGenics

ThromboGenics

ThromboGenics

ThromboGenics is a biopharmaceutical company focused on developing innovative treatments for eye disease, with a focus on diabetic eye disease.

 

The company’s pipeline of disease modifying drug candidates is targeting the key segments of the diabetic eye disease market: diabetic retinopathy with or without diabetic macular edema. ThromboGenics owns the global rights to JETREA® (ocriplasmin), the only pharmacological vitreolysis drug approved for the treatment of symptomatic vitreomacular adhesion (in the US) and vitreomacular traction (in Europe and elsewhere) in over 54 countries worldwide.

 

ThromboGenics is headquartered in Leuven, Belgium, and is listed on the NYSE Euronext Brussels exchange under the symbol THR.

Flanders.bio Strategic Partners